Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

Triptorelin

AFDA Approved
65
Moderate Credibility
1 cited studyy · Evidence level A

GnRH receptor agonist (decapeptide) · 10 amino acids · Brand: Trelstar, Triptodur, Decapeptyl

FDA ApprovedPrescription Required

Triptorelin is a synthetic decapeptide agonist of gonadotropin-releasing hormone (GnRH), approved by the FDA for advanced prostate cancer, central precocious puberty, and endometriosis. It suppresses sex hormone production through pituitary desensitization.

Mechanism of Action

Initially stimulates LH and FSH release (flare effect), but continuous exposure desensitizes GnRH receptors in the anterior pituitary, downregulating gonadotropin secretion. This leads to suppressed testosterone (in males) or estrogen (in females), achieving chemical castration or ovarian suppression.

Benefits

  • First-line androgen deprivation therapy for prostate cancer[1]
  • Halts progression of central precocious puberty in children
  • Treats endometriosis and uterine fibroids via ovarian suppression
  • Used in fertility preservation and assisted reproduction protocols
Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

Triptorelin — Dosing in Published Research

Reported Routes: Intramuscular injection, Subcutaneous injection
Prostate cancer: 3.75 mg IM monthly, 11.25 mg IM every 3 months, or 22.5 mg IM every 6 months. CPP: 22.5 mg IM every 6 months. Endometriosis: 3.75 mg IM monthly for up to 6 months. Anti-androgen therapy may be co-administered for first 2 weeks to block flare.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Initial testosterone flare (first 1-2 weeks; may worsen bone pain)
  • Hot flashes, decreased libido, erectile dysfunction
  • Bone mineral density loss (osteoporosis risk with long-term use)
  • Metabolic changes (increased fat mass, insulin resistance)
  • Mood changes, fatigue

Ready to Discuss Triptorelin with a Doctor?

Triptorelin is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Find a Prescribing Provider

Telehealth consultations available in most states

FDA ApprovedBoard-Certified DoctorsPrescription if Appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Approved Treatment Routing

Triptorelin in PeptideScholar's current approved-treatment dataset

Triptorelin is currently modeled on this site as an approved treatment path for: Advanced prostate cancer; central precocious puberty; endometriosis; preoperative treatment of uterine leiomyomata. Brand names in the current dataset: Trelstar, Triptodur, Decapeptyl.

Validation Note
This block reflects the site's current structured treatment data and internal routing logic. It is not a substitute for checking current prescribing, labeling, payer, or local regulatory details.

Research & Evidence

RCTEur Urol, 2014

Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.

Intermittent triptorelin monotherapy was non-inferior to continuous maximal androgen blockade for overall survival in metastatic prostate cancer, with better quality of life

PMID: 23582949

References

  1. 1. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group.. Eur Urol, 2014. Intermittent triptorelin monotherapy was non-inferior to continuous maximal androgen blockade for overall survival in metastatic prostate cancer, with better quality of life [PMID: 23582949]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

GLP-1 Support Essentials

Products to help manage side effects and optimize outcomes during treatment.

Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.

Progress Tracking Tools

Monitor weight, body composition, and nutrition to maximize results.

Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.

Triptorelin FAQ

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get peptide research updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.